Gene expression analysis of E16.5 Stk11-sufficient control and Sk11-/- lungs
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA479877 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR7475526.fastq.gz | Fastqsanger.gz | |||
| SRR7475527.fastq.gz | Fastqsanger.gz | |||
| SRR7475528.fastq.gz | Fastqsanger.gz | |||
| SRR7475529.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 4 of 4 |
Similar Datasets
Project description:Functional properties of mucosal surfaces are dependent on establishing the correct proportions of specialized epithelial cell types. In the mammalian airway, the proportions of ciliated and secretory cells types are tightly regulated to ensure efficient mucociliary clearance. Ciliated cells are one of the first mature cell types to be specified by differentiation of multipotent endodermal progenitors of the developing lung and can be replaced postnatally by differentiation of secretory progenitors. In each case, cell cycle exit is a necessary, early step that precedes differentiation. However, the relationship between cell cycle exit and cell fate determination is poorly understood. We show that the serine-threonine kinase Stk11 controls the cell cycle exit in airway stem/progenitor cells via phosphorylation and activation of the AMPK-related kinase Mark3, which directly suppresses Erk1/2 mediated Rb inactivation. Our study demonstrates that Stk11-dependent cell cycle exit accounts for the normal program of ciliated cell differentiation in developing and postnatal airways.
2018-07-06 | GSE116690 | GEO
Project description:Rosa26rtTA;tetOsFgfr2b (C75Bl6) induced from E16.5 until E18.5, lungs were harvest at E18.5, AECI and AECII were sorted using FACS. Mice were kept on water and food ad libitum.
2021-06-01 | GSE115878 | GEO
Project description:Single cell RNA-sequencing on E16.5 and E17.5 mouse lungs
| PRJNA657548 | ENA
Project description:In this experiment we inhibited FGF signalling in E16.5 mouse lungs by using a dominant negative mouse model. We are interested in assessing the genetic regulation by FGF signalling at this stage of lung development. Specifically, we used a tetracycline controlled transcriptional activation model (Tet(o)) to manipulate FGF signalling. Genetically modified male mice that expressed a reverse tetracycline-controlled trans activator (rtTA) on the Rosa26 locus and a soluble FGFR2b on the Tet(o) promoter (Tet(o)sFgfr2b) (B6.Cg-Gt(ROSA)26Sortm1.1(rtTA,EGFP)NagyTg(tetO-Fgfr2b/Igh)1.3Jaw/sbel), were crossed with females lacking the Tet(o)sFgfr2b allele. Pregnant females were injected with doxycycline intraperitonally at E16.5. Doxycycline then induced the transcription soluble FGFR2b in the embryos, which inhibited FGF signalling by sequestering FGF ligands, preventing them from binding to the native FGFR2b receptor. We harvested embryonic lungs after 9 hrs of inhibition. We took the left lobe of each sample for RNA isolation. We set-up our matings so that 50% of the embryos in a litter were expected to contain the soluble FGFR2b. The remaining littermates will serve as the control group. We will compare the gene expression profiles of the experimental embryonic lungs with those of littermate controls.
2021-06-01 | GSE115877 | GEO
Project description:In-vivo inhibition of Fgfr2b signalling in embryonic whole mouse lungs at E16.5
| PRJNA476352 | ENA
Project description:We performed RNA-sequencing of mouse cells derived from colony forming assays (CFA) to evaluate the transcriptome of MPN cells with deletion of the tumor suppressor STK11/LKB1 and relative controls. The CFA are from mouse primary floxed STK11 hematopoietic stem and progenitor cells (HSPCs) transduced with retroviruses encoding the MPN mutation MPLW515L and CRE recombinase to delete STK11.
2021-01-27 | GSE159737 | GEO
Project description:Epithelial (CD31-CD45-EpCAM+) cells were isolated by FACS from Grhl2-deficient (Shh-Cre;Grhl2f/-) and control (Shh-Cre;Grhl2f/+) embryonic lungs at day E16.5 (3 biological replicates/genotype). Total RNA extracted from the samples was subjected to next-generation sequencing (NGS) library preparation using standard Illumina protocols. Completed libraries from individual samples were sequenced on a HiSeq2500 at the Australian Genome Research Facility.
2018-12-03 | GSE105781 | GEO
Project description:Mutations in STK11/LKB1 in non-small cell lung cancer (NSCLC) are associated with poor patient responses to immune checkpoint blockade (ICB) and introduction of a Stk11/Lkb1 (L) mutation into murine lung adenocarcinomas driven by mutant Kras and Trp53 loss (KP) resulted in an ICB refractory syngeneic KPL tumor. Mechanistically this occurred because KPL mutant NSCLCs lacked TCF1-expressing CD8 T cells, a phenotype recapitulated in human STK11/LKB1 mutant NSCLCs. Systemic inhibition of Axl results in increased type I interferon secretion from dendritic cells that expanded tumor-associated TCF1+ PD-1+ CD8 T cells, restoring therapeutic response to PD-1 ICB for KPL tumors. This was observed in syngeneic immunocompetent mouse models and in humanized mice bearing STK11/LKB1 mutant NSCLC human tumor xenografts. NSCLC patients with identified STK11/LKB1 mutations receiving bemcentinib and pembrolizumab demonstrated objective clinical response to combination therapy. We conclude that AXL is a critical targetable driver of immune suppression in STK11/LKB1 mutant NSCLC.
2022-01-24 | GSE194166 | GEO
Project description:While mutations in the KRAS oncogene are amongst the most prevalent in human cancer, there are few successful treatments to target these tumors. It is also likely that heterogeneity in KRAS-mutant tumor biology significantly contributes to the response to therapy. We hypothesized that presence of commonly co-occurring mutations in STK11 and TP53 tumor suppressors may represent a significant source of heterogeneity in KRAS-mutant tumors. To address this, we utilized a large cohort of resected tumors from 442 lung adenocarcinoma patients with data including annotation of prevalent driver mutations (KRAS, EGFR) and tumor suppressor mutations (STK11 and TP53), microarray-based gene expression and clinical covariates including overall survival (OS). Specifically, we determined impact of STK11 and TP53 mutations on a new KRAS mutation-associated gene expression signature as well as previously defined signatures of tumor cell proliferation and immune surveillance responses. Interestingly, STK11, but not TP53 mutations, were associated with highly elevated expression of KRAS mutation-associated genes. Mutations in TP53 and STK11 also impacted tumor biology regardless of KRAS status, with TP53 strongly associated with enhanced proliferation and STK11 with suppression of immune surveillance. These findings illustrate the remarkably distinct ways through which tumor suppressor mutations may contribute to heterogeneity in KRAS-mutant tumor biology. In addition, these studies point to novel associations between gene mutations and immune surveillance that could impact the response to immunotherapy.
2015-10-21 | GSE72094 | GEO
Project description:Transcriptional profiling of BL/6 mice harboring a mutant Kras allele, with or without knockouts of Stk11 and/or Keap1, or with expression of an Nfe2l2 transgene, Nrf2Tg. In lung adenocarcinoma (LUAD), stabilization of the transcription factor NRF2 through genomic alterations in KEAP1 and NFE2L2 occurs in roughly a quarter of patients, often in the context of STK11 tumor suppressor loss. In this study, we demonstrate that NRF2 activation in the context of concurrent KRAS mutation and STK11 loss promotes aggressive LUAD tumor behavior in both human and mouse preclinical models. This phenotype is associated with metabolic rewiring and rescue by NRF2 of redox stress, high in STK11 null tumors. Applying a novel, pan-lung cancer, diagnostic NRF2 activation gene expression signature that is independent of frequently co-occurring mutations, we dissect the independent contributions of the three most frequent genetic events in human LUAD (NRF2 activation, STK11 loss and KRAS mutations) on patient prognosis and clinical responses in a dataset of second-line LUAD patients treated with immunotherapy or chemotherapy (OAK trial). Our findings underscore that both individual effects and epistatic relationships among oncogenic and tumor suppressor pathways influence tumor biology, immune contexture and patient clinical outcomes. Our work also highlights the value of lung cancer disease sub-classification based on genetic and expression profiling as part of patient clinical management.
2020-01-31 | GSE133714 | GEO